Integra LifeSciences (IART) Expected to Announce Earnings on Monday

Integra LifeSciences (NASDAQ:IART) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 5th. Analysts expect Integra LifeSciences to post earnings of $0.43 per share and revenue of $381.17 million for the quarter.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.85 by $0.12. The firm had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.89 EPS. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Integra LifeSciences Price Performance

IART opened at $16.85 on Friday. Integra LifeSciences has a twelve month low of $14.45 and a twelve month high of $32.66. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -187.20, a PEG ratio of 0.73 and a beta of 1.24. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a fifty day simple moving average of $19.94 and a 200 day simple moving average of $22.10.

Analyst Upgrades and Downgrades

IART has been the subject of a number of analyst reports. Truist Financial reduced their price target on Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a report on Friday, April 11th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, March 31st. Three analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and an average target price of $22.71.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.